Ovarian cancer provides an up-to-date and comprehensive synthesis of clinical management and research progress in the field of epithelial ovarian cancer. The book has its origins in two separate but complementary initiatives. One initiative was a series of reviews commissioned to cover the spectrum of clinical management of ovarian cancer from prevention, screening and diagnosis to surgery, chemotherapy and palliative care. The reviews were invited from an international panel of clinicians with expertise in the management of ovarian cancer. The second initiative was co-ordinated by the Helene Harris Memorial Trust (HHMT) which has organised key biennial meetings on ovarian cancer for the last 12 years. Attendance at the meetings is by invitation to a small group of international authorities on research aspects of ovarian cancer. Setting the clinically focused reviews alongside the HHMT research focused chapters has created a unique book. First, the book is unusually up-to-date and presents recent advances not included in other books in this field.
Second, the contents are comprehensive and cover aetiology, pathology, screening, prevention, diagnosis, prognostic techniques, surgery, adjuvant therapy and palliative care. Third, the review chapters are set alongside more detailed coverage of recent clinical and basic science developments. Examples of this are the coverage of familial cancer, prevention, screening, and current therapy which are consequently much more topical and exciting. Fourth, there are sections on 'tumour biology' and 'novel therapies' which have not been covered in comparable books about ovarian cancer. Finally, the contributions are from a representative spectrum of experts from both research and clinical backgrounds and with a truly international perspective.
Auflage
Sprache
Verlagsort
Zielgruppe
Editions-Typ
Illustrationen
4 colour plates, numerous black & white photographs and line illustrations
ISBN-13
978-0-19-850826-7 (9780198508267)
Copyright in bibliographic data is held by Nielsen Book Services Limited or its licensors: all rights reserved.
Schweitzer Klassifikation
Introduction; PART 1: AETIOLOGY; 1. Epidemiology of sporadic ovarian cancer; 2. Associations between infertility, its treatment and ovarian cancer risk; 3. The molecular basis of sporadic ovarian cancer; 4. Overview of the aetiology of familial ovarian cancer; 5. The prevalence of mutations in BRCA1 and BRCA2; 6. The penetrance of BRCA1/2 mutations; 7. Founder mutations of BRCA1/2; 8. Clinical implications of genetic testing; PART 2: NATURAL HISTORY AND PATHOLOGY; 9. Pathology of epithelial ovarian cancer; 10. Pathology of borderline ovarian malignancy; 11. Primary non-epithelial ovarian cancers; 12. Metastases in the ovary; 13. Genetic analysis of putative precursors of ovarian cancer; 14. Molecular pathogenesis of borderline and invasive ovarian tumours; PART 3: TUMOR BIOLOGY; 15. The application of novel technology to the study of ovarian cancer; 16. The biology of the ovarian surface epithelium; 17. The tumour microenvironment of epithelial ovarian cancer; 18. ARHI (NOEY2), a novel imprinted tumour suppressor gene in ovarian cancer; 19. Regulation of angiogenesis in ovarian cancer: role of p53, vascular endothelial growth factor, and hypoxia; 20. Role of Fas/FasL in the control of human ovary growth and progression; PART 4: PREVENTION AND SCREENING; 21. The surgical prevention of ovarian cancer; 22. Chemoprevention of ovarian cancer; 23. Biologic effect of progestins on ovarian epithelium: cancer prevention through apoptosis?; 24. The current status of screening for ovarian cancer; 25. Optimising the use of ultrasonography in ovarian cancer screening; 26. Doppler ultrasound derived indices in screening and diagnosis of ovarian cancer; 27. Differentiating the risk of ovarian cancer calculation from CA125 velocity: a new concept for optimizing CA125 screening for ovarian cancer; 28. Socioeconomics of ovarian cancer screening; 29. The management of familial ovarian cancer; PART 5: DIAGNOSTIC AND PROGNOSTIC TECHNIQUES; 30. Clinical diagnosis including para-neoplastic syndromes; 31. Serum tumour markers in the clinical management of ovarian cancer; 32. Three-dimensional ultrasound and color-flow studies; 33. CT and MRI of ovarian cancer; 34. Radionuclide imaging; 35. Telomerase in ovarian cancer: possible diagnostic test and therapeutic target; 36. Detection of circulating tumour cells in the peripheral blood and bone marrow of patients with ovarian cancer; PART 6: SURGICAL MANAGEMENT OF OVARIAN CANCER; 37. Overview of primary surgery for ovarian cancer; 38. Interval debulking surgery significantly increases the survival and progression-free survival in advanced epithelial ovarian cancer patients: an EORTC Gynaecological Cancer Co-operative Group study; 39. The role of surgery in relapse and palliation of ovarian cancer; 40. The role of minimal access surgery in ovarian cancer; 41. The organization of care; 42. Patterns of care in ovarian cancer; PART 7: ADJUVANT AND PALLIATIVE THERAPY FOR OVARIAN CANCER; 43. Current chemotherapy options in ovarian cancer; 44. Chemotherapy for epithelial cancer of the ovary; 45. Neoadjuvant chemotherapy in advanced ovarian carcinoma: present and future prospects; 46. Randomized trials in epithelial ovarian cancer: the Gynaecological Oncology Group studies; PART 8: NOVEL THERAPIES: THE FUTURE; 47. Angiogenesis in epithelial ovarian cancer: an important biological event and therapeutic target; 48. Delivery of genes to ovarian cancer using targeted vectors based on self-assembling polymers; 49. Corporate drug discovery strategies; 50. DNA mismatch repair and drug resistance; 51. Gene therapy and immunomodulation; 52. Preclinical and phase 1 clinical studies of combinations of chemotherapy with recombinant adenovirus containing full-length, human p53 tumor suppressor gene cDNA for p53-mutant ovarian cancer; 53. Paclitaxel resistance in human ovarian cancer: role of apoptosis-related proteins; 54. Trials of p53 gene therapy: rationale and preliminary studies; 55. Phosphatidylinostol 3'-kinase as a target in ovarian cancer: from genomics to therapeutics
